WO2012141554A3 - 접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도 - Google Patents

접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도 Download PDF

Info

Publication number
WO2012141554A3
WO2012141554A3 PCT/KR2012/002873 KR2012002873W WO2012141554A3 WO 2012141554 A3 WO2012141554 A3 WO 2012141554A3 KR 2012002873 W KR2012002873 W KR 2012002873W WO 2012141554 A3 WO2012141554 A3 WO 2012141554A3
Authority
WO
WIPO (PCT)
Prior art keywords
cotinine
antibody
binder material
binding substance
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/002873
Other languages
English (en)
French (fr)
Other versions
WO2012141554A2 (ko
WO2012141554A8 (ko
Inventor
정준호
박선영
황도빈
이화경
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SNU R&DB Foundation filed Critical SNU R&DB Foundation
Priority to KR1020137029242A priority Critical patent/KR101648960B1/ko
Priority to JP2014505086A priority patent/JP5838486B2/ja
Priority to CN201280018671.XA priority patent/CN103476798B/zh
Priority to AU2012243512A priority patent/AU2012243512B2/en
Priority to US14/111,133 priority patent/US9867886B2/en
Priority to EP12772034.0A priority patent/EP2700653B1/en
Publication of WO2012141554A2 publication Critical patent/WO2012141554A2/ko
Publication of WO2012141554A3 publication Critical patent/WO2012141554A3/ko
Anticipated expiration legal-status Critical
Publication of WO2012141554A8 publication Critical patent/WO2012141554A8/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)

Abstract

본 발명은 접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도에 관한 것으로, 본 발명에 따른 복합체는 생체외 생물학적 분석 방법(in vitro biological assay)에 있어서 분석 도구로 사용될 수 있으며, 접합 물질의 특이적 반응성 및 생물학적 기능과, 항체의 고유 특성인 보체 매개 세포 독성(CDC), 항체 의존성 세포 독성(ADCC), 및 긴 생체내 반감기를 보유할 수 있다.
PCT/KR2012/002873 2011-04-15 2012-04-16 접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도 Ceased WO2012141554A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020137029242A KR101648960B1 (ko) 2011-04-15 2012-04-16 접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도
JP2014505086A JP5838486B2 (ja) 2011-04-15 2012-04-16 接合物質とコチニンとの接合体に抗−コチニン抗体が結合した複合体およびその用途
CN201280018671.XA CN103476798B (zh) 2011-04-15 2012-04-16 在粘合物质和可铁宁的粘合体上结合有抗‑可铁宁抗体的复合体及其用途
AU2012243512A AU2012243512B2 (en) 2011-04-15 2012-04-16 Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof
US14/111,133 US9867886B2 (en) 2011-04-15 2012-04-16 Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof
EP12772034.0A EP2700653B1 (en) 2011-04-15 2012-04-16 Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161476018P 2011-04-15 2011-04-15
US61/476,018 2011-04-15

Publications (3)

Publication Number Publication Date
WO2012141554A2 WO2012141554A2 (ko) 2012-10-18
WO2012141554A3 true WO2012141554A3 (ko) 2013-01-10
WO2012141554A8 WO2012141554A8 (ko) 2013-10-24

Family

ID=47009880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002873 Ceased WO2012141554A2 (ko) 2011-04-15 2012-04-16 접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도

Country Status (7)

Country Link
US (1) US9867886B2 (ko)
EP (1) EP2700653B1 (ko)
JP (1) JP5838486B2 (ko)
KR (2) KR101648960B1 (ko)
CN (1) CN103476798B (ko)
AU (1) AU2012243512B2 (ko)
WO (1) WO2012141554A2 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013137686A1 (ko) 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
KR102157701B1 (ko) * 2015-08-17 2020-09-21 서울대학교산학협력단 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도
WO2017222310A1 (ko) * 2016-06-21 2017-12-28 서울대학교산학협력단 이중 특이성 항체를 이용한 항체 약물 복합체 플랫폼
KR102122546B1 (ko) * 2017-01-05 2020-06-15 한국생명공학연구원 항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포
CN110475857B (zh) * 2017-01-05 2023-07-18 韩国生命工学研究院 表达抗-可替宁嵌合抗原受体的天然杀伤细胞
WO2018211126A1 (en) 2017-05-19 2018-11-22 Philip Morris Products S.A. Diagnostic test for distinguishing the smoking status of a subject
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用
KR102506295B1 (ko) 2020-08-28 2023-03-08 국립암센터 디그옥시제닌에 대한 인간화 항체 및 이의 용도
KR102506288B1 (ko) 2020-09-07 2023-03-06 국립암센터 디그옥시제닌에 대한 항체를 포함하는 복합체, 및 이들의 용도
PT4384223T (pt) * 2021-08-13 2026-01-08 Glaxosmithkline Ip Dev Ltd Quimeras dirigidas à citotoxicidade para células que expressam ccr2
US20250136722A1 (en) * 2021-08-13 2025-05-01 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras
WO2023161876A1 (en) * 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for cxcr3-expressing cells
WO2023161879A1 (en) * 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
WO2023161878A1 (en) * 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for folate receptor-expressing cells
WO2023161875A1 (en) * 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
WO2023161877A1 (en) * 2022-02-25 2023-08-31 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for integrin avb6-expressing cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049667A2 (en) * 2000-12-20 2002-06-27 Smithkline Beecham P.L.C Vaccine for treating nicotine addiction
KR20070107687A (ko) * 2004-12-31 2007-11-07 제넨테크, 인크. Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
US20080226650A1 (en) * 2007-03-14 2008-09-18 Park Sunyoung Cotinine neutralizing antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8506102D0 (en) * 1985-03-08 1985-04-11 Baylor College Medicine Monoclonal antibodies
EP0194158A3 (en) 1985-03-08 1988-02-24 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays
US5500375A (en) * 1993-04-13 1996-03-19 Serex, Inc. Integrated packaging-holder device for immunochromatographic assays in flow-through or dipstick formats
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
KR100352030B1 (en) * 2002-01-10 2002-09-11 Orion Corp Gum composition for removing nicotine
WO2010090762A1 (en) * 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
JP5927194B2 (ja) * 2010-09-24 2016-06-01 マリンクロッド エルエルシー 治療ナノキャリアおよび／または診断ナノキャリアのターゲティングのためのアプタマーコンジュゲート

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049667A2 (en) * 2000-12-20 2002-06-27 Smithkline Beecham P.L.C Vaccine for treating nicotine addiction
KR20070107687A (ko) * 2004-12-31 2007-11-07 제넨테크, 인크. Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
US20080226650A1 (en) * 2007-03-14 2008-09-18 Park Sunyoung Cotinine neutralizing antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARK, S. ET AL.: "A sensitive enzyme immunoassay for measuring continine in passive smokers", CLINICA CHIMICA ACTA, vol. 411, no. 17-18, 11 May 2010 (2010-05-11), pages 1238 - 1242, XP027104801 *
SCHEPERS, G. ET AL.: "Cotinine determination by immunoassays may be influenced by other nicotine metabolites", ARCH TOXICOL, vol. 62, no. ISSUE, December 1988 (1988-12-01), pages 395 - 397, XP008172282 *

Also Published As

Publication number Publication date
KR20160105959A (ko) 2016-09-08
AU2012243512B2 (en) 2016-04-07
WO2012141554A2 (ko) 2012-10-18
CN103476798B (zh) 2017-04-05
EP2700653A2 (en) 2014-02-26
US9867886B2 (en) 2018-01-16
CN103476798A (zh) 2013-12-25
JP2014517819A (ja) 2014-07-24
AU2012243512A1 (en) 2013-11-21
KR101648960B1 (ko) 2016-08-22
JP5838486B2 (ja) 2016-01-06
KR101827962B1 (ko) 2018-02-13
EP2700653B1 (en) 2019-07-24
KR20140027219A (ko) 2014-03-06
US20140056926A1 (en) 2014-02-27
WO2012141554A8 (ko) 2013-10-24
EP2700653A4 (en) 2014-11-12

Similar Documents

Publication Publication Date Title
WO2012141554A8 (ko) 접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도
MY161909A (en) Anti-her3 antibodies and uses thereof
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2010145792A8 (en) Bispecific antigen binding proteins
AU2009283199A8 (en) Antibodies to CCR2
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
GB201014805D0 (en) Microfluidics based assay device
ZA201003496B (en) Monoclonal antibody capable of binding to anexelekto,and use thereof
PH12013500810B1 (en) Anti-il-23 antibodies
NZ593297A (en) Myostatin binding proteins
WO2007084321A3 (en) Antibodies to ox-2/cd200 and uses thereof
WO2013188693A8 (en) Antigen binding constructs to cd3
WO2011133704A3 (en) Modified polypeptides and proteins and uses thereof
EP2282770A4 (en) FCRN ALTERNATED BINDING ANTIBODIES AND METHODS OF USING THE SAME
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
MX340683B (es) Anticuerpos anti-vla-4.
WO2009055074A3 (en) Erbb2 binding proteins and use thereof
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
EP2105447A4 (en) ANTIBODIES OF AVIAN ORIGIN CAPABLE OF SPECIFICALLY BINDING TO HUMAN HMGB1, METHOD OF IMMUNOLOGICAL DETERMINATION FOR HUMAN HMGB1, AND IMMUNOLOGICAL DETERMINATION REAGENT FOR HUMAN HMGB1
WO2011096894A3 (en) Use of novel markers of pluripotent stem cells
MY151976A (en) Insulin assay
WO2010136483A3 (en) Antigen-binding proteins
GB0718843D0 (en) Materials and methods relating to modifying the binding of antibodies
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12772034

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014505086

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137029242

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14111133

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012772034

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2012243512

Country of ref document: AU

Date of ref document: 20120416

Kind code of ref document: A